



# Radiance Biopharma to Present at The Microcap Conference 2025

---

*Microcap Conference Presentation*

*Venue: the Borgata Hotel Spa & Casino in Atlantic City, NJ.*

*Date: Thursday, January 30, 2025*

*Time: 2:00 pm EST*

ATLANTIC CITY, NJ, UNITED STATES, January 28, 2025 /EINPresswire.com/ -- Radiance Biopharma to Present at The Microcap Conference 2025

– Radiance Biopharma, a clinical stage biotechnology company developing next generation Antibody Drug Conjugates (ADCs), announced it will present at the Microcap Conference, being held January 28-30, 2025, in Atlantic City, N.J.

Management will deliver a corporate presentation and engage in meetings with institutional and individual investors to discuss the company's development, growth strategy, and investment opportunities.

## About Radiance Biopharma

Radiance is a clinical stage biotechnology company developing next generation Antibody Drug Conjugates (ADCs) for the treatment of cancer. RB-164, is a 'Best in Class', anti-ROR-1 ADC, for the treatment of liquid and solid tumors. RB-201, is a 'First in Class' anti- HER2/TROP2 Bispecific ADC, utilizing next generation tandem linker-payload technology, for the treatment of solid tumors.

Contacts For more information, please visit [www.radiancebiopharma.com](http://www.radiancebiopharma.com) Contact us at [Info@radiancebiopharma.com](mailto:Info@radiancebiopharma.com) Office Tel. 617.621.7143

Robert Brooks  
Radiance Biopharma

6176217143 ext.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/781037229>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.